Aurobindo Pharma Limited

“Aurobindo is a vertically integrated generics operator with a durable but narrow API cost moat, a credible injectable pivot in slow motion, and a clean balance sheet — but its oral-solid-heavy US revenue mix faces structural price erosion, ROIIC barely clears the cost of capital, governance carries unresolved promoter criminal-charge overhang and opaque related-party complexity, and at 18.8x forward earnings near a 52-week high there is no margin of safety; the expected 10-12% annualised return matches but does not beat the Indian equity market while absorbing meaningfully higher company-specific risk, making this NEUTRAL — capital is better deployed in higher-conviction compounders.”